This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Molina (MOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Molina Healthcare (MOH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Molina (MOH) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?
by Zacks Equity Research
Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).
Molina (MOH) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC) Wins Contract to Serve Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) Indiana subsidiary receives a contract from the Indiana Department of Administration, thereby continuing to serve the unique health needs of Indiana communities.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDY
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops
by Zacks Equity Research
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH